Rocket Pharmaceuticals Issues 345,911 RSUs; 383,854 Options at $3.18
Rhea-AI Filing Summary
Insider equity awards and option grants were recorded for Rocket Pharmaceuticals (RCKT). The reporting person, the company’s Chief Medical Officer, was issued 283,018 restricted stock units (RSUs) that convert one-for-one to common shares and an additional 62,893 RSUs, for a total beneficial ownership of 345,911 shares after the transactions. The filing also shows a grant of 383,854 non-qualified stock options exercisable at $3.18 per share with an exercisable start on 10/06/2028 and expiration on 10/06/2035.
Vesting schedules are time-based: one-third of the larger RSU and option awards vest on 10/06/2026, with the remainder vesting quarterly over two years; the smaller RSU award vests half on 10/06/2026 and fully by the second anniversary. All vesting is subject to continued employment.
Positive
- Alignment with shareholders via combined RSUs and NQSOs that vest over multi-year periods
- Retention-focused vesting schedules (one-third or half at first anniversary, remainder over the following two years)
- Substantial long-term incentive with options expiring on 10/06/2035, encouraging long-horizon performance
Negative
- Potential dilution from 345,911 RSUs converting to common shares upon vesting
- Further dilution if $3.18 NQSOs (383,854) are exercised in the future
- No performance conditions disclosed; vesting is solely time-based and depends only on continued employment
Insights
Grants align the Chief Medical Officer with shareholder outcomes but create near-term dilution.
The package combines RSUs and NQSOs to provide both guaranteed equity value at vesting and leverage through options exercisable at $3.18. Time-based vesting over two to three years ties realized gain to continued employment, supporting retention.
Risks include dilution from converting 345,911 RSUs and exercising 383,854 options; investors should note the exercisable window beginning 10/06/2028
These awards are material in share count terms but not a cash expense now.
RSUs convert to common stock one-for-one and increase outstanding share count when vested; options require payment of $3.18 per share to realize, so they do not create immediate cash outflows for the company but will dilute equity if exercised. The grants have long expirations (10/06/2035), giving extended optionality to the holder.
Monitor the company’s overall outstanding equity and option pool utilization over the next 2 years to assess dilution impact as vesting occurs.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 383,854 | $0.00 | -- |
| Grant/Award | Common Stock | 283,018 | $0.00 | -- |
| Grant/Award | Common Stock | 62,893 | $0.00 | -- |
Footnotes (1)
- Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries. Represents non-qualified stock options ("NQSOs") that convert to common stock on a one-for-one basis. One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
